Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies. Thus, they present a good opportunity for investors seeking a mix of growth and stability.
To get an idea of the returns you could make (or lose) in the short term by investing in mid-cap stocks, detailed below are the five best and worst performing mid-cap stocks in Dec 2022.
Five Best Performing Mid-Cap Stocks In Dec 2022
Q4 2022 hedge fund letters, conferences and more
Founded in 2018 and headquartered in New York City, this company focuses on developing treatments for patients with autoimmune diseases. Immunovant Inc (NASDAQ:IMVT) shares are up by almost 117% in the last three months and up almost 147% in the last year.
As of this writing, Immunovant shares are trading above $19.80 with a 52-week range of $3.15 to $19.98, giving the company a market capitalization of more than $2.50 billion.
Headquartered in New York City, this company offers software and services to businesses for managing travel, expenses, meetings and events. Global Business Travel Group Inc (NYSE:GBTG) shares are up by over 26% in the last three months but are down by over 28% in the last year.
As of this writing, Global Business Travel Group shares are trading above $6.10 with a 52-week range of $4.26 to $10.01, giving the company a market cap of more than $3.20 billion.
Founded in 1969 and headquartered in Westminster, Colo., this company delivers space technology solutions, including satellites, robotics and more. Maxar Technologies Inc (NYSE:MAXR) shares are up by almost 148% in the last three months and up almost 72% in the last year.
As of this writing, Maxar Technologies shares are trading above $50 with a 52-week range of $17.51 to $51.93, giving the company a market capitalization of more than $3.70 billion.
Founded in 2016 and headquartered in San Diego, Calif., this company develops novel precision therapeutics and companion diagnostics for gastroenterology and autoimmune diseases. Prometheus Biosciences Inc (NASDAQ:RXDX) shares are up by over 93% in the last three months and up over 200% in the last year.
As of this writing, Prometheus Biosciences shares are trading above $105 with a 52-week range of $21.50 to $117.73, giving the company a market cap of more than $4.90 billion.
Founded in 2011 and headquartered in Fort Washington, Pa., this company develops therapeutic candidates for treating cardiovascular, metabolic and liver diseases. Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) shares are up by over 274% in the last three months and up almost 264% in the last year.
As of this writing, Madrigal Pharmaceuticals shares are trading above $279 with a 52-week range of $52.33 to $315.45, giving the company a market capitalization of more than $4.80 billion.
Five Worst Performing Mid-Cap Stocks In Dec 2022
Here are the five worst performing mid-cap stocks in Dec 2022:
Founded in 2014 and headquartered in Cambridge, Mass., it is a genome editing company that develops curative therapeutics using the CRISPR/Cas9 system. Intellia Therapeutics Inc (NASDAQ:NTLA) shares are down by almost 30% in the last three months and down over 63% in the last year.
As of this writing, Intellia Therapeutics shares are trading above $38 with a 52-week range of $32.72 to $108.00, giving the company a market cap of more than $3.20 billion.
Founded in 2013 and headquartered in New York City, it is an online neutral video platform. Rumble Inc (NASDAQ:RUM) shares are down by almost 44% in the last three months and down over 44% in the last year.
As of this writing, Rumble shares are trading above $6.70 with a 52-week range of $5.81 to $18.52, giving the company a market cap of more than $2.50 billion.
Founded in 1920 and headquartered in Leawood, Kan., it is a holding company that is in the business of theatrical exhibition. AMC Entertainment Holdings Inc (NYSE:AMC) shares are down by over 41% in the last three months and down over 72% in the last year.
As of this writing, AMC Entertainment shares are trading above $3.80 with a 52-week range of $3.77 to $21.0895, giving the company a market capitalization of more than $2 billion.
Founded in 2012 and headquartered in Palo Alto, Calif., this company focuses on treating cancer through proprietary blood-based tests, vast data sets and advanced analytics. Guardant Health Inc (NASDAQ:GH) shares are down by over 53% in the last three months and down over 70% in the last year.
As of this writing, Guardant Health shares are trading above $25 with a 52-week range of $24.63 to $94.55, giving the company a market cap of more than $2.60 billion.
Founded in 1995 and headquartered in San Diego, Calif., this company develops novel therapeutics targeting genetic and immunological promoters of cancer. Mirati Therapeutics Inc (NASDAQ:MRTX) shares are down by almost 33% in the last three months and down over 66% in the last year.
As of this writing, Mirati Therapeutics shares are trading above $44 with a 52-week range of $32.96 to $131.64, giving the company a market capitalization of more than $2.50 billion.
